Literature DB >> 32061334

Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study.

Stijn E Verleden1, Naoya Tanabe2, John E McDonough1, Dragoş M Vasilescu3, Feng Xu3, Wim A Wuyts1, Davide Piloni4, Laurens De Sadeleer1, Stijn Willems1, Cindy Mai5, Jeroen Hostens6, Joel D Cooper7, Erik K Verbeken1, Johny Verschakelen5, Craig J Galban8, Dirk E Van Raemdonck1, Thomas V Colby9, Marc Decramer1, Geert M Verleden1, Naftali Kaminski10, Tillie-Louise Hackett3, Bart M Vanaudenaerde1, James C Hogg11.   

Abstract

BACKGROUND: The observation that patients with idiopathic pulmonary fibrosis (IPF) can have higher than normal expiratory flow rates at low lung volumes led to the conclusion that the airways are spared in IPF. This study aimed to re-examine the hypothesis that airways are spared in IPF using a multiresolution imaging protocol that combines multidetector CT (MDCT), with micro-CT and histology.
METHODS: This was a retrospective cohort study comparing explanted lungs from patients with severe IPF treated by lung transplantation with a cohort of unused donor (control) lungs. The donor control lungs had no known lung disease, comorbidities, or structural lung injury, and were deemed appropriate for transplantation on review of the clinical files. The diagnosis of IPF in the lungs from patients was established by a multidisciplinary consensus committee according to existing guidelines, and was confirmed by video-assisted thoracic surgical biopsy or by pathological examination of the contralateral lung. The control and IPF groups were matched for age, sex, height, and bodyweight. Samples of lung tissue were compared using the multiresolution imaging approach: a cascade of clinical MDCT, micro-CT, and histological imaging. We did two experiments: in experiment 1, all the lungs were randomly sampled; in experiment 2, samples were selected from regions of minimal and established fibrosis. The patients and donors were recruited from the Katholieke Universiteit Leuven (Leuven, Belgium) and the University of Pennsylvania Hospital (Philadelphia, PA, USA). The study took place at the Katholieke Universiteit Leuven, and the University of British Columbia (Vancouver, BC, Canada).
FINDINGS: Between Oct 5, 2009, and July 22, 2016, explanted lungs from patients with severe IPF (n=11), were compared with a cohort of unused donor (control) lungs (n=10), providing 240 samples of lung tissue for comparison using the multiresolution imaging approach. The MDCT specimen scans show that the number of visible airways located between the ninth generation (control 69 [SD 22] versus patients with IPF 105 [33], p=0·0023) and 14th generation (control 9 [6] versus patients with IPF 49 [28], p<0·0001) of airway branching are increased in patients with IPF, which we show by micro-CT is due to thickening of their walls and distortion of their lumens. The micro-CT analysis showed that compared with healthy (control) lung anatomy (mean 5·6 terminal bronchioles per mL [SD 1·6]), minimal fibrosis in IPF tissue was associated with a 57% loss of the terminal bronchioles (mean 2·4 terminal bronchioles per mL [SD 1·0]; p<0·0001), the appearance of fibroblastic foci, and infiltration of the tissue by inflammatory immune cells capable of forming lymphoid follicles. Established fibrosis in IPF tissue had a similar reduction (66%) in the number of terminal bronchioles (mean 1·9 terminal bronchioles per mL [SD 1·4]; p<0·0001) and was dominated by increased airspace size, Ashcroft fibrosis score, and volume fractions of tissue and collagen.
INTERPRETATION: Small airways disease is a feature of IPF, with significant loss of terminal bronchioles occuring within regions of minimal fibrosis. On the basis of these findings, we postulate that the small airways could become a potential therapeutic target in IPF. FUNDING: Katholieke Universiteit Leuven, US National Institutes of Health, BC Lung Association, and Genentech.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32061334      PMCID: PMC7292784          DOI: 10.1016/S2213-2600(19)30356-X

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  34 in total

1.  Quantification of idiopathic pulmonary fibrosis using computed tomography and histology.

Authors:  H O Coxson; J C Hogg; J R Mayo; H Behzad; K P Whittall; D A Schwartz; P G Hartley; J R Galvin; J S Wilson; G W Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  1997-05       Impact factor: 21.405

2.  Nondestructive cryomicro-CT imaging enables structural and molecular analysis of human lung tissue.

Authors:  Dragoş M Vasilescu; André B Phillion; Naoya Tanabe; Daisuke Kinose; David F Paige; Jacob J Kantrowitz; Gang Liu; Hanqiao Liu; Nick Fishbane; Stijn E Verleden; Bart M Vanaudenaerde; Marc Lenburg; Christopher S Stevenson; Avrum Spira; Joel D Cooper; Tillie-Louise Hackett; James C Hogg
Journal:  J Appl Physiol (1985)       Date:  2016-11-17

3.  Stereological assessment of mouse lung parenchyma via nondestructive, multiscale micro-CT imaging validated by light microscopic histology.

Authors:  Dragos M Vasilescu; Christine Klinge; Lars Knudsen; Leilei Yin; Ge Wang; Ewald R Weibel; Matthias Ochs; Eric A Hoffman
Journal:  J Appl Physiol (1985)       Date:  2012-12-20

4.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors:  Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2011-05-13       Impact factor: 79.321

5.  The site and nature of airway obstruction after lung transplantation.

Authors:  Stijn E Verleden; Dragoş M Vasilescu; Stijn Willems; David Ruttens; Robin Vos; Elly Vandermeulen; Jeroen Hostens; John E McDonough; Erik K Verbeken; Johny Verschakelen; Dirk E Van Raemdonck; Benoît Rondelet; Christiane Knoop; Marc Decramer; Joel Cooper; James C Hogg; Geert M Verleden; Bart M Vanaudenaerde
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

6.  Linking clinical phenotypes of chronic lung allograft dysfunction to changes in lung structure.

Authors:  Stijn E Verleden; Dragoş M Vasilescu; John E McDonough; David Ruttens; Robin Vos; Elly Vandermeulen; Hannelore Bellon; Rachel Geenens; Erik K Verbeken; Johny Verschakelen; Dirk E Van Raemdonck; Wim A Wuyts; Youri Sokolow; Christiane Knoop; Joel D Cooper; James C Hogg; Geert M Verleden; Bart M Vanaudenaerde
Journal:  Eur Respir J       Date:  2015-06-25       Impact factor: 16.671

7.  Small-airway obstruction and emphysema in chronic obstructive pulmonary disease.

Authors:  John E McDonough; Ren Yuan; Masaru Suzuki; Nazgol Seyednejad; W Mark Elliott; Pablo G Sanchez; Alexander C Wright; Warren B Gefter; Leslie Litzky; Harvey O Coxson; Peter D Paré; Don D Sin; Richard A Pierce; Jason C Woods; Annette M McWilliams; John R Mayo; Stephen C Lam; Joel D Cooper; James C Hogg
Journal:  N Engl J Med       Date:  2011-10-27       Impact factor: 91.245

8.  Micro-Computed Tomography Comparison of Preterminal Bronchioles in Centrilobular and Panlobular Emphysema.

Authors:  Naoya Tanabe; Dragoş M Vasilescu; John E McDonough; Daisuke Kinose; Masaru Suzuki; Joel D Cooper; Peter D Paré; James C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

9.  Association Between Interstitial Lung Abnormalities and All-Cause Mortality.

Authors:  Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake
Journal:  JAMA       Date:  2016-02-16       Impact factor: 56.272

10.  The nature of small-airway obstruction in chronic obstructive pulmonary disease.

Authors:  James C Hogg; Fanny Chu; Soraya Utokaparch; Ryan Woods; W Mark Elliott; Liliana Buzatu; Ruben M Cherniack; Robert M Rogers; Frank C Sciurba; Harvey O Coxson; Peter D Paré
Journal:  N Engl J Med       Date:  2004-06-24       Impact factor: 91.245

View more
  16 in total

1.  Human distal lung maps and lineage hierarchies reveal a bipotent progenitor.

Authors:  Preetish Kadur Lakshminarasimha Murthy; Vishwaraj Sontake; Aleksandra Tata; Yoshihiko Kobayashi; Lauren Macadlo; Kenichi Okuda; Ansley S Conchola; Satoko Nakano; Simon Gregory; Lisa A Miller; Jason R Spence; John F Engelhardt; Richard C Boucher; Jason R Rock; Scott H Randell; Purushothama Rao Tata
Journal:  Nature       Date:  2022-03-30       Impact factor: 69.504

Review 2.  From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?

Authors:  Jacob E Michalski; Jonathan S Kurche; David A Schwartz
Journal:  Transl Res       Date:  2021-09-20       Impact factor: 10.171

3.  Lung Microenvironments and Disease Progression in Fibrotic Hypersensitivity Pneumonitis.

Authors:  Laurens J De Sadeleer; John E McDonough; Jonas C Schupp; Xiting Yan; Arno Vanstapel; Anke Van Herck; Stephanie Everaerts; Vincent Geudens; Annelore Sacreas; Tinne Goos; Celine Aelbrecht; Tim S Nawrot; Dries S Martens; Dominique Schols; Sandra Claes; Johny A Verschakelen; Eric K Verbeken; Maximilian Ackermann; Anabelle Decottignies; Manon Mahieu; Tillie-Louise Hackett; James C Hogg; Bart M Vanaudenaerde; Stijn E Verleden; Naftali Kaminski; Wim A Wuyts
Journal:  Am J Respir Crit Care Med       Date:  2022-01-01       Impact factor: 21.405

Review 4.  Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.

Authors:  Paolo Spagnolo; Jonathan A Kropski; Mark G Jones; Joyce S Lee; Giulio Rossi; Theodoros Karampitsakos; Toby M Maher; Argyrios Tzouvelekis; Christopher J Ryerson
Journal:  Pharmacol Ther       Date:  2020-12-24       Impact factor: 13.400

5.  Integrin Axis Regulates Airway Biophysical Dysfunction in Idiopathic Pulmonary Fibrosis.

Authors:  Ian T Stancil; Jacob E Michalski; David A Schwartz
Journal:  Am J Respir Cell Mol Biol       Date:  2022-02       Impact factor: 7.748

6.  Club Cell Loss as a Feature of Bronchiolization in ILD.

Authors:  Paul Reynaud; Engi Ahmed; Isabelle Serre; Lucie Knabe; Sébastien Bommart; Carey Suehs; Isabelle Vachier; Jean Philippe Berthet; Micaela Romagnoli; Charlotte Vernisse; Jean Pierre Mallet; Anne Sophie Gamez; Arnaud Bourdin
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 7.  Stereology as the 3D tool to quantitate lung architecture.

Authors:  Lars Knudsen; Christina Brandenberger; Matthias Ochs
Journal:  Histochem Cell Biol       Date:  2020-10-13       Impact factor: 4.304

Review 8.  Irreversibility of Pulmonary Fibrosis.

Authors:  Qing Yang Yu; Xiao Xiao Tang
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745

9.  Pulmonary fibrosis distal airway epithelia are dynamically and structurally dysfunctional.

Authors:  Ian T Stancil; Jacob E Michalski; Duncan Davis-Hall; Hong Wei Chu; Jin-Ah Park; Chelsea M Magin; Ivana V Yang; Bradford J Smith; Evgenia Dobrinskikh; David A Schwartz
Journal:  Nat Commun       Date:  2021-07-27       Impact factor: 17.694

10.  Paramyxovirus replication induces the hexosamine biosynthetic pathway and mesenchymal transition via the IRE1α-XBP1s arm of the unfolded protein response.

Authors:  Dianhua Qiao; Melissa Skibba; Xiaofang Xu; Roberto P Garofalo; Yingxin Zhao; Allan R Brasier
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-07-28       Impact factor: 6.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.